Skip to main content
Terug
AUPH logo

Aurinia Pharmaceuticals Inc.

Datakwaliteit: 100%
AUPH
NASDAQ Healthcare Biotechnology
€ 14,21
▼ € 0,35 (-2,40%)
Marktkapitalisatie: 1,89B
Dagbereik
€ 13,85 € 14,56
52-Weeksbereik
€ 6,83 € 16,54
Volume
1.479.594
50D / 200D Gem.
€ 14,57 / € 12,72
Vorige Slotkoers
€ 14,56

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 6,6 0,3
P/B 3,3 2,9
ROE % 59,9 3,7
Net Margin % 101,5 3,8
Rev Growth 5Y % 57,8 10,0
D/E 0,1 0,2

Koersdoel Analisten

Hold
€ 15,50 +9.1%
Low: € 15,00 High: € 16,00
Forward K/W
17,9
Forward WPA
€ 0,81
WPA Groei (sch.)
+0,0%
Omzet Sch.
330 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 1,64
€ 1,56 – € 1,84
 520 M 2
FY2029 € 1,26
€ 1,19 – € 1,41
 470 M 2
FY2028 € 1,27
€ 0,43 – € 2,12
 440 M 4

Belangrijkste Punten

Revenue grew 57,84% annually over 5 years — strong growth
Earnings grew 4893,08% over the past year
ROE of 59,91% indicates high profitability
Net margin of 101,47% shows strong profitability
Debt/Equity of 0,13 — conservative balance sheet
Generating 135,41M in free cash flow

Groei

Revenue Growth (5Y)
57,84%
Revenue (1Y)20,38%
Earnings (1Y)4893,08%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
59,91%
ROIC11,99%
Net Margin101,47%
Op. Margin37,06%

Veiligheid

Debt / Equity
0,13
Current Ratio5,25
Interest Coverage24,23

Waardering

P/E Ratio
6,58
P/B Ratio3,25
EV/EBITDA17,96
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 20,38% Revenue Growth (3Y) 26,99%
Earnings Growth (1Y) 4893,08% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 57,84% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 283,06M Net Income (TTM) 287,20M
ROE 59,91% ROA 38,21%
Gross Margin 88,46% Operating Margin 37,06%
Net Margin 101,47% Free Cash Flow (TTM) 135,41M
ROIC 11,99% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,13 Current Ratio 5,25
Interest Coverage 24,23 Dividend Yield 0,00%
Valuation
P/E Ratio 6,58 P/B Ratio 3,25
P/S Ratio 6,68 PEG Ratio 0,00
EV/EBITDA 17,96 Dividend Yield 0,00%
Market Cap 1,89B Enterprise Value 1,88B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 283,06M 235,13M 175,51M 134,03M 45,61M
Net Income 287,20M 5,75M -78,02M -108,18M -180,97M
EPS (Diluted) 2,07 0,04 -0,54 -0,76 -1,40
Gross Profit 250,39M 206,89M 161,37M 128,37M 44,51M
Operating Income 104,91M -4,69M -91,69M -111,47M -180,74M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 751,59M 550,65M 548,06M 470,86M 543,37M
Total Liabilities 170,26M 173,17M 170,11M 65,43M 64,28M
Shareholders' Equity 581,33M 377,48M 377,95M 405,44M 479,09M
Total Debt 74,81M 79,37M 97,61M 8,09M 8,74M
Cash & Equivalents 80,21M 83,43M 48,88M 94,17M 231,90M
Current Assets 491,97M 446,60M 424,80M 442,54M 513,32M
Current Liabilities 93,72M 97,76M 77,19M 46,11M 40,65M

Strategiescores

This stock passed the criteria for 6 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Capital Light Compounder
#50 of 218
53
Custom Contrarian Investing (David Dreman)
#5 of 670
95
Growth Growth Investing (Philip Fisher)
#30 of 157
79
Value Value Investing (Warren Buffett)
#6 of 203
63
Custom Full Throttle
#127 of 146
27
Custom Lower Risk
#40 of 140
51

Recente Activiteit

Ingestapt Capital Light Compounder
Mar 24, 2026
Ingestapt Contrarian Investing (David Dreman)
Mar 24, 2026
Ingestapt Growth Investing (Philip Fisher)
Mar 24, 2026
Ingestapt Value Investing (Warren Buffett)
Mar 24, 2026
Ingestapt Full Throttle
Mar 24, 2026
Ingestapt Lower Risk
Mar 24, 2026